Summit Therapeutics Inc.
Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines for serious unmet medical needs, with a pipeline centered on oncology. Its lead candidate is ivonescimab, a bispecific antibody licensed from Akeso for development and commercialization in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa. Summit is conducting Phase III trials of ivonescimab for non-small cell lung cancer and colorectal cancer, including studies of the drug alone and in combination with chemotherapy or other medicines. Summit submitted a biologics license application for ivonescimab with chemotherapy in a proposed lung cancer indication, and the FDA accepted it for filing in January 2026. Summit’s operations focus on developing ivonescimab and other potential activities. Under its license agreement, Summit may owe Akeso regulatory and sales-based milestone payments and royalties on annual sales in the licensed territories, and it purchases some clinical and commercial supply from Akeso. Summit is headquartered in Miami, Florida.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SMMT in the last 30 days.
See all $SMMT insider activity →BioXcel (BTAI), Cytokinetics (CYTK), and Summit (SMMT) await FDA decisions on Nov.14, 2026. BioXcel's IGALMI, Cytokinetics' MYQORZO, and Summit's Ivonescimab are under review.
Stifel reduced its price target for Summit Therapeutics (NASDAQ:SMMT) to $37 from $38, maintaining a Buy rating. The stock trades at $14.88, below the $12-$44 analyst consensus. Summit reported faster-than-expected enrollment in colorectal cancer trials and confirmed AstraZeneca's $2B investment. Analysts note strong liquidity but no expected profitability this year. Recent analyst updates include reaffirmed ratings and varied price targets.
Summit Therapeutics Inc. (SMMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 4, 2026, Summit Therapeutics Inc. (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-296642) with the Securities and Exchange Commission. This Current Report on Form 8-K
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SMMT (Summit Therapeutics Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent SMMT coverage spans financial news, regulation and earnings.
FDA BLA outcome will likely cause significant movement.
Analyst price target cut suggests reduced upside expectations.
The filing indicates the company may issue new shares, which could dilute existing shareholders.
Earnings show narrowed loss but large cash infusion; FDA outcome will drive near‑term price.
Potential FDA approval could lift the stock; a delay or negative decision could pressure it.
AlphAI scores every news story that mentions SMMT with an AI model for sentiment and relevance, and aggregates insider trades from Summit Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioXcel (BTAI), Cytokinetics (CYTK), and Summit (SMMT) await FDA decisions on Nov.14, 2026. BioXcel's IGALMI, Cytokinetics' MYQORZO, and Summit's Ivonescimab are under review.
Stifel reduced its price target for Summit Therapeutics (NASDAQ:SMMT) to $37 from $38, maintaining a Buy rating. The stock trades at $14.88, below the $12-$44 analyst consensus. Summit reported faster-than-expected enrollment in colorectal cancer trials and confirmed AstraZeneca's $2B investment. Analysts note strong liquidity but no expected profitability this year. Recent analyst updates include reaffirmed ratings and varied price targets.
Summit Therapeutics Inc. (SMMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 4, 2026, Summit Therapeutics Inc. (the “Company”) filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-296642) with the Securities and Exchange Commission. This Current Report on Form 8-K
Summit Therapeutics reported a Q3 2026 GAAP net loss of $208.4M ($0.26/sh), improved from $231.8M y/y. The company received a $2.0B investment from AstraZeneca post-quarter, ending with $629.8M in cash. The FDA decision on ivonescimab is pending with a PDUFA goal date of November 14, 2026.
Revolution Medicines' pancreatic cancer drug approval validated its technology and supported its $40B+ valuation. Summit Therapeutics, Abivax, and Viking Therapeutics, each with multibillion-dollar valuations, face key tests for their experimental drugs. Summit awaits FDA decision on ivonescimab for lung cancer; Abivax eyes 2026 FDA filing for obefazimod in ulcerative colitis; Viking develops obesity treatments to compete with market leaders.
Citizens reaffirmed a Market Outperform rating and $40 price target for Summit Therapeutics (SMMT) based on Phase 3 trial data. The trial showed improvements in survival rates for a cancer treatment. SMMT has a market cap of $11.6B, trades at $14.50, and holds $2.8B in cash. Analysts have mixed views on its recent developments, including a $2B investment from AstraZeneca.
Jefferies reiterated a Buy rating on Summit Therapeutics (NASDAQ:SMMT) with a $30 price target, citing encouraging pipeline readthroughs and positive data from the European Society for Medical Oncology conference. The stock is currently trading at $14.88, suggesting a potential upside of nearly 100%. Analysts have mixed views, with some highlighting the company's strategic collaboration with AstraZeneca and others expressing skepticism.
Stifel maintained a Buy rating and $38.00 price target for Summit Therapeutics (SMMT) after positive clinical trial data from partner Akeso's HARMONi-GI1 study. The stock is down 47% from its 52-week high, with a market cap of $12.4B. Analysts' price targets range from $11.90 to $43.73. The trial showed promising results for ivonescimab in first-line biliary tract cancer, with a hazard ratio of 0.75. Summit also received a $2B investment from AstraZeneca for cancer treatment development.
AstraZeneca's stomach cancer drug doubled survival, Eli Lilly's lung cancer treatment showed 62% tumor shrinkage, Moderna/Merck's vaccine reduced recurrence risk by 42%, Amgen's therapy extended survival, and Roche's drug outperformed rivals. U.S. stocks fell due to AI jitters and oil price spikes, with Fed rate decisions looming. Earnings reports from Visa, Alphabet, and others are upcoming. TransDigm's stock declined despite strong sales due to higher interest rates and oil price concerns.
Summit Therapeutics reported positive Phase 3 trial results for Ivonescimab in advanced biliary tract cancer. Several pharma companies, including Novartis, Biogen, GSK, Lilly, Merck, and others, are set to report earnings this week. Beam Therapeutics and Benitec Biopharma will present early gene-therapy data. Inovio and Agios await FDA decisions on their respective treatments.
